期刊文献+

荧光原位杂交法检测乳腺癌HER-2/neu表达及临床意义 被引量:7

Determination of HER-2/neu Gene Expression in the Tissue of Breast Cancer by FISH and Its Clinicopathological Implications
下载PDF
导出
摘要 目的探讨用荧光原位杂交(fluorescent in situ hybridization,FISH)方法检测乳腺癌HER-2/neu基因表达的临床意义。方法应用FISH法对2008年1月至2008年7月在首都医科大学附属北京天坛医院就诊的33例女性新发乳腺癌患者进行HER-2/neu基因检测,分析基因表达程度与临床病理特征之间的关系,比较基因和免疫组化(IHC)法蛋白表达的差别。结果33位受试者中HER-2/neu基因过表达率为39.4%,其过表达与肿瘤大小、绝经与否、临床分期之间差异无统计学意义(P>0.05)。该基因在有腋淋巴结转移组显著高于无淋巴结转移组(P<0.05),ER阴性组高于ER阳性组,差异有统计学意义(P<0.01)。PR阴性组与阳性组间差异无统计学意义。P53基因阳性组显著高于阴性组(P<0.05)。HER-2/neu基因过表达者11例为免疫组化HER-2蛋白强阳性病例;2例为中度阳性病例。结论FISH技术可稳定检测乳腺癌中HER-2/neu基因的表达程度,其过表达与绝经与否、肿瘤大小、临床分期无关,与腋淋巴结转移和P53基因表达成正相关,与ER呈密切负相关。HER-2蛋白高强度表达(3+)与基因扩增有极好的一致性,而中等强度表达(2+)必须进一步行FISH法基因检测。 Objective To explore overexpression of HER-2/neu gene by fluorescence in situ hybridization (FISH) in breast cancer and explore the clinical implications. Methods HER-2/neu gene in 33 cases with kainogeneous female breast cancer was detected by FISH from January 2008 up to now, and the relationship between HER-2/neu gene overexpression with clinical and pathological characters investigated. Results HER-2/neu gene expression rate was 39.4%. The overexpression was not correlated with tumor size, menostasis and clinical tumor stage( P 〉 0.05 ). It was positively correlated with axillary lymph node status (P 〈 0.05 ) and P53 gene (P 〈 0.05 ) ; and negatively correlated with ER( P 〈 0.01 ) , but not correlated with PR ( P 〉 0.05 ). The overexpression cases with HER-2/neu gene showed 11 strongly and 5 moderately positive expression of HER-2 protein by immunohistochemistry. Conclusion FISH technique could detect the overexpression of HER-2/neu gene in breast cancer. It has favourable concordance with strongly positive expression of HER-2 protein(3 + ) , but in the of moderately positive cases, FISH must be applied.
出处 《首都医科大学学报》 CAS 北大核心 2009年第1期93-96,共4页 Journal of Capital Medical University
基金 卫生部科研基金(WKJ2007-3-001)资助项目~~
关键词 乳腺癌 HER-2/NEU基因 荧光原位杂交技术 breast cancer HER-2/neu gene fluorescent in situ hybridization
  • 相关文献

参考文献12

  • 1Shin S J, Hyjek E, Early E, et al. Intratumoral heterogeneity of her-2/neu in invasive mammary carcinomas using fluorescence in situ hybridization and tissue microarray [ J]. Int J Surg Pathol, 2006,14:279-284.
  • 2焦德,任国胜.HER 2基因在乳腺癌中的研究进展[J].国外医学(外科学分册),2005,32(5):374-378. 被引量:3
  • 3Leong T Y, Leong A S. Controversies in the assessment of HER-2: more questions than answers [ J ]. Adv Anat Pathol, 2006,13:263-269.
  • 4Lan C, Liu J M, Liu T W, et al. Cerb-B2 amphfication by fluorescence in situ hybridization in breast cancer specimens read as 2 + in immunohistochemical analysis [ J]. Am J Clin Pathol, 2005,124:97-102.
  • 5Dolan M ,Snover D. Comparison of immunohistochemical and fluorescence in situ hybridization assessment of HER22 status in routine practice [ J ]. Am J Clin Pathol, 2005, 123:766-770.
  • 6Press M F, Sauter G, Bernstein L, et al. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials[ J]. Clin Cancer Res, 2005,11 : 6598- 6607.
  • 7Jacobs T W, Gown A M, Yaziji H, et al. HER-2/neu protein expression in breast cancer evaluated by immunohisto- chemistry: a study of interlaboratory agreement [ J]. Am J Clin Pathol, 2000,113:251-258.
  • 8Horiguchi J, Koibuchi Y, Lijima K, et al. Co-expressed type of ER and HER-2 protein as a predictive factor in determining resistanee to antiestrogen therapy in patients with ER-positive and HER2-positive breast cancer [ J]. Oncol Rep, 2005,14:1109- 1116.
  • 9谢永红,林雪平,李继承.绝经前和绝经后乳腺癌患者中ER、nm23-H1、c-erbB-2基因的表达及其关系[J].实用肿瘤杂志,2007,22(2):150-152. 被引量:2
  • 10Yamanchi H, Steams V, Hayes D F. The role of c-erb B-2 as a predictive factor in breast cancer[ J ]. Breast Cancer, 2001,8 : 171-183.

二级参考文献7

共引文献3

同被引文献70

  • 1刘彤华.表皮生长因子受体家族与靶向性抗癌治疗[J].中华病理学杂志,2006,35(10):577-579. 被引量:21
  • 2曾瑄,梁智勇,武莎斐,周炜洵,高洁,刘彤华.乳腺癌HER2蛋白表达阳性者的基因状态分析[J].中华病理学杂志,2006,35(10):584-588. 被引量:40
  • 3王跃华,王全红,李丽,肖彦增,殷卫东,杨宣琴,王丽霞,王晋芬.乳腺癌Her-2基因检测方法对比[J].临床与实验病理学杂志,2007,23(2):225-226. 被引量:11
  • 4步宏,郑杰.美国临床肿瘤学会/美国病理学医师学院乳腺癌HER2检测指南简介[J].中华病理学杂志,2007,36(7):496-497. 被引量:24
  • 5Kasof G M,Comes B C.Livin a novel inhibitor of apoptosis protein family member.J Biol Chem.2001,276 (2):3238-3246.
  • 6Shin S J,Hyjek E,Early E,et al.Intratumoral heterogeneity of her-2/neu in invasive mammary carcinomas using flu oreseence in situ hybridization and tissue microarray.Int J Surg Pathol,2006.14:279-284.
  • 7Hammock L,Lewis M,Phillips C,et al.Strong Her2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization.Hum Pathol.2005.36:1043-1047.
  • 8Wolff AC,Hammond ME,Schwartz JN,et al.American Society of Clinical Oneology/College of American Pathologists guideline recommendations for Human Epidermal Growth Factor Receptor 2 testing in breast cancer.Arch Pathol Lab Med,2007,131 (1):18-43.
  • 9Press M F,Sauter G,Bernstein L,et al.Diagnostic evaluation of HER-2 as a molecular target:an assessment of accuracy and reproducibility of laboratory testing in large,prospective,randomized clinical trials.Clin Cancer Res,2005,11:6598-6607.
  • 10Berry DA,Cronin KA,Plevritis SK,et al.Effect of screening and adjuvant therapy on mortality from breast cancer[J].N Engl J Med,2005,353(17):1784-1792.

引证文献7

二级引证文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部